{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:51:10Z","timestamp":1777477870947,"version":"3.51.4"},"reference-count":69,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.3892\/ijo.2015.3180","type":"journal-article","created":{"date-parts":[[2015,9,23]],"date-time":"2015-09-23T07:13:11Z","timestamp":1442992391000},"page":"1696-1702","source":"Crossref","is-referenced-by-count":27,"title":["The Eltrombopag antitumor effect on hepatocellular carcinoma"],"prefix":"10.3892","volume":"47","author":[{"given":"TOMOHIRO","family":"KUROKAWA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SOICHIRO","family":"MURATA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUN-WEN","family":"ZHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KENICHI","family":"IWASAKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KEISUKE","family":"KOHNO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KIYOSHI","family":"FUKUNAGA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NOBUHIRO","family":"OHKOHCHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,9,23]]},"reference":[{"key":"key20180107190853_b1-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180107190853_b2-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1749-6632.2002.tb04090.x","article-title":"Epidemiology, risk factors, and natural history of hepatocellular carcinoma","volume":"963","author":"Montalto","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"key20180107190853_b3-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180107190853_b4-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"key20180107190853_b5-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1053\/j.gastro.2011.03.006","article-title":"Targeted therapies for hepatocellular carcinoma","volume":"140","author":"Villanueva","year":"2011","journal-title":"Gastroenterology"},{"key":"key20180107190853_b6-ijo-47-05-1696","first-page":"6","article-title":"Thrombopoietin: The novel hepatic hormone","volume":"17","author":"Wolber","year":"2002","journal-title":"News Physiol Sci"},{"key":"key20180107190853_b7-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1084\/jem.183.2.651","article-title":"Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin","volume":"183","author":"de Sauvage","year":"1996","journal-title":"J Exp Med"},{"key":"key20180107190853_b8-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1038\/sj.onc.1205323","article-title":"The molecular and cellular biology of thrombopoietin: The primary regulator of platelet production","volume":"21","author":"Kaushansky","year":"2002","journal-title":"Oncogene"},{"key":"key20180107190853_b9-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2141.2006.06215.x","article-title":"Megakaryocyte development and platelet production","volume":"134","author":"Deutsch","year":"2006","journal-title":"Br J Haematol"},{"key":"key20180107190853_b10-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1073\/pnas.92.8.3234","article-title":"Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development","volume":"92","author":"Kaushansky","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107190853_b11-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"key":"key20180107190853_b12-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMoa073255","article-title":"Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C","volume":"357","author":"McHutchison","year":"2007","journal-title":"N Engl J Med"},{"key":"key20180107190853_b13-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood-2009-04-219493","article-title":"Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"114","author":"Will","year":"2009","journal-title":"Blood"},{"key":"key20180107190853_b14-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.leukres.2010.02.005","article-title":"Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag","volume":"34","author":"Erickson-Miller","year":"2010","journal-title":"Leuk Res"},{"key":"key20180107190853_b15-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood-2011-12-399667","article-title":"Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation","volume":"120","author":"Roth","year":"2012","journal-title":"Blood"},{"key":"key20180107190853_b16-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/1471-2407-12-405","article-title":"Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors","volume":"12","author":"Erickson-Miller","year":"2012","journal-title":"BMC Cancer"},{"key":"key20180107190853_b17-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1007\/s00535-012-0600-5","article-title":"Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: A randomized, open-label, phase II study","volume":"47","author":"Kawaguchi","year":"2012","journal-title":"J Gastroenterol"},{"key":"key20180107190853_b18-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0091270010368677","article-title":"Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers","volume":"51","author":"Matthys","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"key20180107190853_b19-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"key20180107190853_b20-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2006-10-047753","article-title":"Iron chelation regulates cyclin D1 expression via the proteasome: A link to iron deficiency-mediated growth suppression","volume":"109","author":"Nurtjahja-Tjendraputra","year":"2007","journal-title":"Blood"},{"key":"key20180107190853_b21-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.V91.3.923","article-title":"Thrombopoietin and its receptor, c-mpl, are constitutively expressed by mouse liver endothelial cells: Evidence of thrombopoietin as a growth factor for liver endothelial cells","volume":"91","author":"Cardier","year":"1998","journal-title":"Blood"},{"key":"key20180107190853_b22-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MEG.0b013e3282f246e6","article-title":"Thrombopoietin is a growth factor for rat hepatic progenitors","volume":"20","author":"Schmelzer","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key20180107190853_b23-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/hepr.12006","article-title":"Effects of thrombopoietin on growth of hepatocellular carcinoma: Is thrombopoietin therapy for liver disease safe or not?","volume":"43","author":"Nozaki","year":"2013","journal-title":"Hepatol Res"},{"key":"key20180107190853_b24-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exphem.2004.09.006","article-title":"Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist","volume":"33","author":"Erickson-Miller","year":"2005","journal-title":"Exp Hematol"},{"key":"key20180107190853_b25-ijo-47-05-1696","first-page":"2912","article-title":"Biological activity and selectivity for Tpo receptor of the orally bioavailable, small molecule Tpo receptor agonist, SB-497115","volume":"104","author":"Erickson-Miller","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"key20180107190853_b26-ijo-47-05-1696","first-page":"2913","article-title":"Effects of SB559457, a novel small molecule thrombopoietin receptor (TpoR) agonist, on human hematopoietic cell growth and differentiation","volume":"104","author":"Kalota","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"key20180107190853_b27-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.bmcl.2005.11.096","article-title":"New benzimidazoles as thrombopoietin receptor agonists","volume":"16","author":"Safonov","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"key20180107190853_b28-ijo-47-05-1696","first-page":"2910","article-title":"Discovery of SB-497115, a small-molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia","volume":"104","author":"Luengo","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"key20180107190853_b29-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.drudis.2008.06.002","article-title":"Emerging treatments for thrombocytopenia: Increasing platelet production","volume":"13","author":"Peeters","year":"2008","journal-title":"Drug Discov Today"},{"key":"key20180107190853_b30-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1021\/jm025535c","article-title":"Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics","volume":"45","author":"Duffy","year":"2002","journal-title":"J Med Chem"},{"key":"key20180107190853_b31-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1021\/jm0255365","article-title":"Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics","volume":"45","author":"Duffy","year":"2002","journal-title":"J Med Chem"},{"key":"key20180107190853_b32-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2009.04.010","article-title":"Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: Two single-dose, open-label, randomized-sequence, crossover studies","volume":"31","author":"Williams","year":"2009","journal-title":"Clin Ther"},{"key":"key20180107190853_b33-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0950-3536(05)80133-7","article-title":"Control of disease by selective iron depletion: A novel therapeutic strategy utilizing iron chelators","volume":"7","author":"Hershko","year":"1994","journal-title":"Baillieres Clin Haematol"},{"key":"key20180107190853_b34-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2174\/1568026043387269","article-title":"Iron chelators in cancer chemotherapy","volume":"4","author":"Buss","year":"2004","journal-title":"Curr Top Med Chem"},{"key":"key20180107190853_b35-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJM199912233412607","article-title":"Disorders of iron metabolism","volume":"341","author":"Andrews","year":"1999","journal-title":"N Engl J Med"},{"key":"key20180107190853_b36-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1182\/blood.V86.6.2268.bloodjournal8662268","article-title":"Effects of iron-depletion on cell cycle progression in normal human T lymphocytes: Selective inhibition of the appearance of the cyclin A-associated component of the p33cdk2 kinase","volume":"86","author":"Lucas","year":"1995","journal-title":"Blood"},{"key":"key20180107190853_b37-ijo-47-05-1696","first-page":"3968","article-title":"Neuroblastoma sensitivity to growth inhibition by deferrioxamine: Evidence for a block in G1 phase of the cell cycle","volume":"53","author":"Brodie","year":"1993","journal-title":"Cancer Res"},{"key":"key20180107190853_b38-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1040-8428(01)00213-X","article-title":"The iron metabolism of neoplastic cells: Alterations that facilitate proliferation?","volume":"42","author":"Kwok","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180107190853_b39-ijo-47-05-1696","first-page":"31","article-title":"The role of iron in cell cycle progression and the proliferation of neoplastic cells","volume":"1603","author":"Le","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"key20180107190853_b40-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","article-title":"The evolution of iron chelators for the treatment of iron overload disease and cancer","volume":"57","author":"Kalinowski","year":"2005","journal-title":"Pharmacol Rev"},{"key":"key20180107190853_b41-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jss.400110415","article-title":"Modulation of cell surface iron transferrin receptors by cellular density and state of activation","volume":"11","author":"Larrick","year":"1979","journal-title":"J Supramol Struct"},{"key":"key20180107190853_b42-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-4889(90)90018-9","article-title":"The uptake of iron and transferrin by the human malignant melanoma cell","volume":"1053","author":"Richardson","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"key20180107190853_b43-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0005-2736(92)90097-6","article-title":"The effect of desferrioxamine and ferric ammonium citrate on the uptake of iron by the membrane iron-binding component of human melanoma cells","volume":"1103","author":"Richardson","year":"1992","journal-title":"Biochim Biophys Acta"},{"key":"key20180107190853_b44-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1016\/S0021-9258(18)62745-0","article-title":"Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas","volume":"245","author":"Elford","year":"1970","journal-title":"J Biol Chem"},{"key":"key20180107190853_b45-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/0024-3205(81)90746-3","article-title":"Role of ribonucleotide reductase in expression in the neoplastic program","volume":"28","author":"Takeda","year":"1981","journal-title":"Life Sci"},{"key":"key20180107190853_b46-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0065-2571(79)90012-8","article-title":"Regulation of ribonucleotide reductase activity and its possible exploitation in chemotherapy","volume":"17","author":"Witt","year":"1978","journal-title":"Adv Enzyme Regul"},{"key":"key20180107190853_b47-ijo-47-05-1696","first-page":"4929","article-title":"Effects of a single course of deferoxamine in neuroblastoma patients","volume":"50","author":"Donfrancesco","year":"1990","journal-title":"Cancer Res"},{"key":"key20180107190853_b48-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood.V69.3.757.757","article-title":"In vitro and in vivo effects of deferoxamine in neonatal acute leukemia","volume":"69","author":"Estrov","year":"1987","journal-title":"Blood"},{"key":"key20180107190853_b49-ijo-47-05-1696","first-page":"437","article-title":"Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells","volume":"1","author":"Kaplinsky","year":"1987","journal-title":"Leukemia"},{"key":"key20180107190853_b50-ijo-47-05-1696","first-page":"433","article-title":"Mechanism of antineuroblastoma activity of deferoxamine in vitro","volume":"112","author":"Blatt","year":"1988","journal-title":"J Lab Clin Med"},{"key":"key20180107190853_b51-ijo-47-05-1696","first-page":"1749","article-title":"Antineuroblastoma activity of desferoxamine in human cell lines","volume":"47","author":"Blatt","year":"1987","journal-title":"Cancer Res"},{"key":"key20180107190853_b52-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood.V98.3.842","article-title":"The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression","volume":"98","author":"Gao","year":"2001","journal-title":"Blood"},{"key":"key20180107190853_b53-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2004-05-1866","article-title":"Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: A link between iron metabolism and proliferation","volume":"104","author":"Le","year":"2004","journal-title":"Blood"},{"key":"key20180107190853_b54-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2007-03-076737","article-title":"Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1\/WAF1 by iron depletion","volume":"110","author":"Fu","year":"2007","journal-title":"Blood"},{"key":"key20180107190853_b55-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1749-6632.1965.tb54077.x","article-title":"The Biochemistry of desferrioxamine and its relation to iron metabolism","volume":"119","author":"Keberle","year":"1964","journal-title":"Ann NY Acad Sci"},{"key":"key20180107190853_b56-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"14901","DOI":"10.1073\/pnas.0604979103","article-title":"A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics","volume":"103","author":"Whitnall","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107190853_b57-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/carcin\/21.5.943","article-title":"Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines","volume":"21","author":"Rakba","year":"2000","journal-title":"Carcinogenesis"},{"key":"key20180107190853_b58-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/0008-5472.CAN-08-1437","article-title":"The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells","volume":"69","author":"Rao","year":"2009","journal-title":"Cancer Res"},{"key":"key20180107190853_b59-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/gut.37.5.727","article-title":"Hepatocellular carcinoma and African iron overload","volume":"37","author":"Gangaidzo","year":"1995","journal-title":"Gut"},{"key":"key20180107190853_b60-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1158\/1078-0432.CCR-10-3099","article-title":"Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies","volume":"17","author":"Ba","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107190853_b61-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1056\/NEJMc1105726","article-title":"Deferoxamine for advanced hepatocellular carcinoma","volume":"365","author":"Yamasaki","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180107190853_b62-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/sj.bjc.6604204","article-title":"Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C","volume":"98","author":"Tanaka","year":"2008","journal-title":"Br J Cancer"},{"key":"key20180107190853_b63-ijo-47-05-1696","first-page":"8697","article-title":"Normalization of elevated hepatic 8-hydroxy-2\u2032-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet","volume":"61","author":"Kato","year":"2001","journal-title":"Cancer Res"},{"key":"key20180107190853_b64-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/ijc.28159","article-title":"Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib","volume":"133","author":"Louandre","year":"2013","journal-title":"Int J Cancer"},{"key":"key20180107190853_b65-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1586\/14737140.8.10.1569","article-title":"Role of thalidomide in previously untreated patients with multiple myeloma","volume":"8","author":"Musto","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20180107190853_b66-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.bbmt.2013.02.013","article-title":"A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma","volume":"19","author":"Mark","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"key20180107190853_b67-ijo-47-05-1696","first-page":"151","article-title":"Repurposing strategies for therapeutics","volume":"24","author":"Sleigh","year":"2010","journal-title":"Pharmaceut Med"},{"key":"key20180107190853_b68-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","article-title":"Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist","volume":"27","author":"Erickson-Miller","year":"2009","journal-title":"Stem Cells"},{"key":"key20180107190853_b69-ijo-47-05-1696","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3892\/ol.2014.1976","article-title":"Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases","volume":"7","author":"Kawaguchi","year":"2014","journal-title":"Oncol Lett"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2015.3180\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T04:40:02Z","timestamp":1653194402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2015.3180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,23]]},"references-count":69,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,9,23]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.3892\/ijo.2015.3180"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2015.3180","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,23]]}}}